Zenas Biopharma Dettes/EBITDA

Que fait Zenas Biopharma ? Zenas Biopharma Inc generates revenue through the development and commercialization of immunology-based therapies, primarily focusing on its lead product candidate obexelimab. This bifunctional monoclonal antibody targets CD19 and FcyRIIb for treating autoimmune diseases without depleting B cells. The company also develops ZB002, an anti-TNFα monoclonal antibody, and ZB004, a CTLA-4-Ig fusion, as part of its global pipeline. Regional programs include ZB001 (VRDN-001) for IGF-1R targeting and ZB005 (DNTH103) for anti-active C1s therapy, all under the company's development and commercialization rights. The company targets patients with autoimmune diseases through its clinical-stage therapies, with obexelimab positioned as a potential franchise for multiple conditions. ZB002 and ZB004 are global programs aimed at broader market reach, while ZB001 and ZB005 are regional initiatives tailored to specific markets. Revenue streams are expected from future commercial sales of these therapies once approved and launched. Zenas Biopharma Inc develops its products internally with a focus on immunology and inflammation, leveraging its pipeline of monoclonal antibodies. The company's business model relies on advancing these candidates through clinical trials to eventual commercialization, with revenue anticipated from the sale of approved therapies to healthcare providers and patients in the target markets. Zenas Biopharma est l'une des entreprises les plus populaires sur Eulerpool.